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Introduction
Targeted integration (TI) allows fast and reproducible
genetic modification of well characterized previously
tagged host cells thus generating producer cells with pre-
dictable qualities. Concurrently, timelines are cut by 50%
compared to random integration (RI) based cell line
development. In contrast to commonly low productivities
of cell lines generated by TI, we developed a system for
CHO cells leading to productivities of more than 1 g/L
within weeks using the TurboCell™ platform.
The system is based on CHO K1 cells that have been
tagged with a GFP expression cassette flanked by
recombinase recognition sites. Following GFP based
FACS enrichment and cloning of the tagged cells, over
4000 clones were screened for growth, productivity,
GFP expression stability and integration status of the
GFP expression cassette. The best clones were selected
to be used as “Master TurboCell” (MTC) host cell lines
for recombinant cell line development.
Generation of producer TurboCell™ lines
A selected MTC host cell line is co-transfected using a
TurboCell™ expression plasmid containing the gene of
interest (GOI) expression cassette flanked by matching
recombinase recognition sites together with a plasmid
encoding the recombinase enzyme required for RMCE.
Upon transfection both plasmids enter the MTC’s
nucleus initiating transient expression of the recombinase
which further mediates the stable exchange of the GFP
expression cassette against the GOI expression cassette.
Thus, the GOI is stably introduced into the tagged geno-
mic spot shortly after the transfection. Cells are cultivated
for a few days to recover from the transfection procedure
and to allow GFP to fade out of RMCE positive cells.
The transfected pools are thereupon sorted by FACS in
order to remove the majority of GFP positive cells. The
remaining producer TurboCell™(PTC) pools in general
comprise of 90-99% GFP negative, GOI expressing cells
that are genetically identical due to the conserved locus
of GOI integration. This allows the production of recom-
binant protein from PTC enriched pools at a very early
stage of 3 weeks upon transfection. Due to their genetic
homogeneity the physiological diversity of the clones
within the pool is limited thus leading to only small var-
iations in the recombinant protein produced. Therefore,
material drug candidate screening prepared on the paren-
tal PTC pool level should only differ slightly from mate-
rial produced from clones thereof. Following FACS
sorting, the PTC pools can be cloned, if required. Due to
the high degree of similarity of all clones, the screening
effort to find the best clone can be limited to about
10 clones. Recombinant protein material from clones can
be produced 9 weeks upon transfection.
Molecular biological analysis of producer
TurboCell™ lines
In order to prove successful RMCE reproducibly taking
place without additional random integration of the
remaining plasmid, genomic DNA was prepared from
clonal PTC for Southern Blot analysis. The genomic
DNA was digested with a restriction enzyme cutting the
correctly integrated targeting vector into two pieces, one
fragment only comprising internal vector sequences, as
well as a second fragment also comprising CHO derived
sequences of the specific integration locus. As both frag-
ments carry sequences of the CMV promotor, both can
be visualized using one single CMV promoter-specific
probe. As only two bands occur in case of successful
RMCE, cell lines showing more than two bands indicate
clones with randomly integrated targeting vector mole-
cules in addition to RMCE. Statistics of several cell line
generation projects show that in about 90% of all* Correspondence: bernd.rehberger@rentschler.de
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analyzed clones a correct RMCE without additional ran-
dom integration events takes place. This allows for a
significant reduction in clone screening efforts to a level
of 10 clones per project.
Process characteristics
To show the feasibility of the TurboCell™ system for
recombinant protein production in fed batch cultiva-
tions, a PTC clone producing IgG1 was cultivated in a
stirred tank bioreactor. The data of this bioreactor were
compared to two shake flask fed batch runs performed
with the same PTC and the same media system (Ren-
tschler’s proprietary media + GE Healthcare’s ActiCHO
feed) in parallel. Figure 1a shows a comparison of viable
cell density and product concentration. The better per-
formance in the bioreactor indicates that the PTC can
be easily transferred from shake flask to bioreactor set-
tings. The maximum cell density of 13*106 cells/mL, as
well as the integral of viable cells over the cultivation
time, and the maximum product titer of more than 1 g/
L IgG1 proved the feasibility of the TurboCell™ system
for the production of recombinant proteins even in lar-
ger amounts at a very early stage of a biopharmaceutical
development project.
Analysis of Protein Quality
Both amount of glycosylation and glycosylation pattern
in different Turbo Cell subsets were analyzed
Figure 1a Comparison of cell growth and recombinant protein production in a bioreactor versus shake flask. Figure 1b: Comparison of
glycopatterns. The first row compares three clones derived from one parental pool of one defined MTC with each other and with the relevant
parental pool. The second row compares mAb material derived from two PTC pools derived from different, not related MTCs. The third row
compares two types of IgG1 antibodies expressed from PTC pools derived from the same MTC.
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Figure 1b shows that clones derived from the same
parental pool differ only slightly regarding their glyco
pattern and they are very similar to their parental pool.
Even if different antibodies are expressed from pools
derived from the same MTC the variation between the
pools is within the range of clones compared to each
other. Significant variations in the glyco pattern can
only be detected, if antibody material derived from
pools descendent from different, unrelated MTCs is
compared (indicated by yellow arrows).
Conclusions
Within 3 weeks upon transfection and targeted integra-
tion, producer cell pools were FACS sorted to purities
of >95%. These cells were suited for high quality recom-
binant protein material production in fed batch runs
exceeding 1 g/L IgG1. Clones generated thereof behaved
similar to the pools in terms of productivity and product
quality, cell growth and metabolism. From those clones
analyzed a mean of about 90% showed successful RMCE
without unintended random integration. Cellular prop-
erties and productivities of the clones were as expected
and variations between different clones were marginal.
Thus, the TurboCell™ system reduces clone screening
efforts to a minimum allowing the simultaneous produc-
tion of multiple recombinant proteins in stable CHO
cells with optimal use of resources. This makes the Tur-
boCell™ system an interesting tool for candidate
screening and early phases material production even in
large scale setups.
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